|Sinovac Reports Positive Phase I Clinical Trial Results For EV71 Vaccine. Amgen Announces New Results From ENBREL.|
|By Staff and Wire Reports|
|Wednesday, 25 May 2011 20:00|
Results of its Phase I clinical trial for Sinovac Biotech Ltd. (NASDAQ:SVA) inactivated vaccine against human enterovirus 71 (EV71), which causes Hand, Foot, and Mouth Disease (HFMD). The safety observation results for the EV71 vaccine for adults, children and infant groups, showed good safety and tolerance profiles and the preliminary immunogenicity study results showed the vaccines can induce good immune responses.
The Phase II clinical trial is scheduled to be commenced within one or two months. The purpose for the Phase II study is to evaluate safety and tolerance of the EV71 vaccine candidates within the expanded population and the vaccine's capability to induce an antibody response to enterovirus 71 to further determine the vaccination dosage. 168 healthy volunteers were enrolled into the Phase I clinical trial in three different groups: adults, young children and infants. The purpose of the Phase I clinical trial was to evaluate the safety and preliminary immunogenicity in the different age groups.
Amgen, Inc. (NASDAQ:AMGN) announced new results from multiple studies of ENBREL, further expanding the supporting the efficacy and safety profile of ENBREL, the prescribed biologic by rheumatologists in the United States.
Eighteen abstracts across four indications, including moderate-to-severe rheumatoid arthritis (RA), ankylosing spondylitis (AS), moderate-to-severe plaque psoriasis (PsO), and psoriatic arthritis (PsA), will be published at two global medical congresses, the European League Against Rheumatism (EULAR) and World Congress of Dermatology (WCD).
Abbott (NYSE:ABT) will present at the Goldman Sachs 32nd Annual Global Healthcare Conference on Wednesday, June 8, 2011.
Advanomics Corporation, the parent company of Sunshine Biopharma Inc. (OTCBB Symbol: SBFM), is pleased to announce that it has recently received an RNA patent in Europe (European Patent Number: 1709199).
Altitude Organic Corporation (PINKSHEETS: ERBB), a leading national, publicly-traded medical marijuana company, announced today it has strategically aligned with medical marijuana advertiser and point-of-sale software support company Cannapages.com.
Amgen (NASDAQ:AMGN) and Pfizer Inc. (NYSE:PFE) today announced new results from multiple studies of ENBREL, further expanding the body of evidence supporting the efficacy and safety profile of ENBREL, the most prescribed biologic by rheumatologists in the United States (U.S.).
Anadys Pharmaceuticals, Inc. (Nasdaq:ANDS), a biopharmaceutical company focused on developing medicines for the treatment of hepatitis C, announced today that it will present data from a previously conducted cancer study of ANA773, the Company's oral immuno-modulator that acts via the TLR-7 pathway, at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.
Cyberonics, Inc. (NASDAQ:CYBX), a global leader in epilepsy management, today announced it will participate in the 2011 Jefferies Global Healthcare Conference on Wednesday, June 8, 2011, in New York.
Cytori Therapeutics (NASDAQ: CYTX) has learned that the Japanese Ministry of Health, Labor and Welfare ("MHLW"), the Japanese health regulatory body, has approved Nagoya University's independent clinical study to assess the efficacy of adipose-derived stem and regenerative cells (ADRCs) in the treatment of stress urinary incontinence.
Deric Haddad, Chief Executive Officer of HWI Global, Inc. (OTCBB: IVTW), the Pittsburgh-based design-build clean-room firm, recently discussed a broad vision for the Company in his 2011 and 2012 forecast. HWI Global also announced a 7:1 forward split and a symbol change to HWIC.
Genesis Biopharma, Inc. (OTCBB: GNBP), a biotechnology company developing targeted cancer therapies, today announced that Patrick Hwu, M.D., and Mario Sznol, M.D., have joined the Company's recently formed Scientific and Medical Advisory Board (SMAB).
InterMune (NASDAQ:ITMN) will outline the company's corporate strategy and vision for 2015, including an update on its ongoing plans to commercialize Esbriet® (pirfenidone) in Europe, as well as details on ASCEND, a new Phase 3 pirfenidone study, during a meeting with analysts in New York tomorrow, May 26.
Phototron Holdings, Inc. (OTCQB: PHOT) (OTCBB: PHOT), the designer, manufacturer and seller of the PHOTOTRON Hydroponic Indoor Grow Systems, today announced the launch of its wholly owned direct selling hydroponic gardening subsidiary, GrowLife Inc.
Radient Pharmaceuticals Corporation "RPC" (NYSE Amex: RPC), a developer and global marketer of In Vitro Diagnostic (IVD) cancer tests, today announced the Company has filed its form 10-K for the fiscal year ended December 31, 2010.
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL), today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.
Shire plc (LSE: SHP, NASDAQ:SHPGY), the global specialty biopharmaceutical company, announces that its subsidiary Shire LLC has received Paragraph IV Notice Letters from Amneal Pharmaceuticals, LLC. ("Amneal") and Watson Laboratories, Inc. ("Watson"), advising of the filing of Abbreviated New Drug Applications ("ANDA") by each company for generic version of all strengths of lisdexamfetamine dimesylate capsules, VYVANSE.
Vermillion, Inc. (NASDAQ:VRML), a molecular diagnostics company, today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for a patent entitled "Saposin D and Fam3C are Biomarkers for Alzheimer's Disease."
VIVUS, Inc. (NASDAQ:VVUS) today announced positive results from a phase 3, placebo-controlled clinical trial of the investigational drug avanafil for the treatment of erectile dysfunction (ED) in patients following a radical prostatectomy.
WaferGen Biosystems, Inc. (OTCBB:WGBS), a leading developer of state-of-the-art genomic analysis systems, today announced it has entered into definitive agreements with three leading institutional life science investors, Great Point Partners, LLC, Deerfield Management and Merlin Nexus, and certain members of the Board and management in a $30.4 million private placement financing of equity and debt.
Watson Pharmaceuticals, Inc. (NYSE:WPI) and Specifar Pharmaceuticals S.A. today jointly announced that Watson has acquired the privately-held multinational generic pharmaceutical developer, manufacturer and marketer for EUR 400 million ($562 million) in cash and certain contingent consideration.